Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of “Buy” from Analysts

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has been given a consensus recommendation of “Buy” by the five research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a strong buy recommendation on the company.

A number of equities analysts recently weighed in on the stock. HC Wainwright upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Friday, December 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Thursday, January 22nd. Zacks Research raised Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. Wall Street Zen raised Inhibikase Therapeutics to a “sell” rating in a research report on Saturday, December 27th. Finally, Cantor Fitzgerald upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Thursday, December 11th.

Inhibikase Therapeutics Price Performance

Shares of NASDAQ:IKT opened at $1.67 on Friday. The company has a fifty day simple moving average of $1.69. The company has a market cap of $125.55 million, a P/E ratio of -4.28 and a beta of 0.84. Inhibikase Therapeutics has a 1 year low of $1.33 and a 1 year high of $3.32.

Inhibikase Therapeutics (NASDAQ:IKT) last issued its earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.